Tradewinds Capital Management’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Tradewinds Capital Management’s Portfolio NWBO Stock Details NWBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-142	Closed	-$1K	–	759
2015 Q2	$1K	Hold	142	–	–	﹤0.01%	655
2015 Q1	$1K	Hold	142	–	–	﹤0.01%	602
2014 Q4	$1K	Hold	142	–	–	﹤0.01%	611
2014 Q3	$1K	Hold	142	–	–	﹤0.01%	583
2014 Q2	$1K	Hold	142	–	–	﹤0.01%	608
2014 Q1	$1K	Sell	142 -58	-29%	-$344	﹤0.01%	618
2013 Q4	$1K	Buy	+200	New	+$774	﹤0.01%	582

Other funds holding NWBO

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Tradewinds Capital Management's NWBO Position: Q3 2015 in Review

Tradewinds Capital Management sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q3 2015, closing a stake of 142 shares — an estimated $1K sold.

Tradewinds Capital Management first reported a position in NWBO in Q4 2013 and held it in 7 quarters. The position peaked at $1K in Q2 2015. 79 funds tracked by Wall St. Rank hold NWBO as of Q3 2015.

Tradewinds Capital Management reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q3 2015 after selling out during the quarter.
Tradewinds Capital Management sold 142 Northwest Biotherapeutics, Inc. Common stock shares in Q3 2015, an estimated $1K.
Tradewinds Capital Management first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q4 2013 and held it in 7 quarters.
Tradewinds Capital Management's Northwest Biotherapeutics, Inc. Common stock position peaked at $1K in Q2 2015.
79 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q3 2015.

Based on Tradewinds Capital Management's 13F filing for Q3 2015, filed 2 Nov 2015.